Key result
A single 200 mg dose of cibenzoline decreased the left ventricular pressure gradient more effectively in HOCM patients with the ACE D allele than in those without it (64 vs 31 mm Hg, P=0.038).
Why the study?
Does a single dose of cibenzoline reduce left ventricular pressure gradient differently based on ACE insertion/deletion polymorphism in patients with hypertrophic obstructive cardiomyopathy?
Observational (n=24)
Does a single dose of cibenzoline reduce left ventricular pressure gradient differently based on ACE insertion/deletion polymorphism in patients with hypertrophic obstructive cardiomyopathy?
Answers are grounded in this paper and cite their sources.
In patients with HOCM, those with the ACE D allele have a higher baseline LVPG and experience a significantly greater reduction in LVPG following a single dose of cibenzoline compared to those without the D allele.
Cibenzoline, a Class I antiarrhythmic agent, can attenuate the left ventricular pressure gradient (LVPG) in patients with hypertrophic obstructive cardiomyopathy (HOCM). An association between the insertion/deletion polymorphism of the angiotensin-converting enzyme (ACE) gene and the progression of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy has been reported. The aim of this study was to investigate the pharmacogenetic interactions between the ACE insertion/deletion polymorphism and the response to cibenzoline in patients with HOCM. Twenty-four patients with HOCM participated in this study. The LVPG and left ventricular function were measured by echocardiography before and 2 hours after administration of a single oral dose of 200 mg cibenzoline. The ACE insertion/deletion polymorphism was genotyped. The frequencies of the genotypes D/D, D/I, and I/I were 16%, 42%, and 42%, respectively. Before administration of cibenzoline, the LVPG was higher in patients with the D allele than in those without it (105 +/- 47 mm Hg versus 64 +/- 24 mm Hg, P = 0.0195). After administration of cibenzoline, the LVPG significantly decreased to 41 +/- 27 mm Hg in those with the D allele (P = 0.0001) and to 33 +/- 24 mm Hg in those without it (P = 0.0003). The LVPG in patients with the D allele was significantly decreased by cibenzoline when compared with patients without the allele (64 +/- 45 mm Hg versus 31 +/- 17 mm Hg, P = 0.038). Patients with HOCM with the ACE D allele had a high LVPG. Cibenzoline was more effective in patients with HOCM with the ACE D allele.
No takes yet. Share an insight, caveat, or question.
Ogimoto et al. (2010) conducted an observational in Hypertrophic obstructive cardiomyopathy (HOCM) (n=24). Cibenzoline vs. Patients without the ACE D allele was evaluated on Decrease in left ventricular pressure gradient (LVPG) (p=0.038). A single 200 mg dose of cibenzoline decreased the left ventricular pressure gradient more effectively in HOCM patients with the ACE D allele than in those without it (64 vs 31 mm Hg, P=0.038).
Synapse has enriched 10 related papers. Consider them for comparative context: